Exenatide vs MGF (Mechano Growth Factor)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Exenatide
Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).
Full details →MGF (Mechano Growth Factor)
MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is produced locally in muscle tissue in response to mechanical stress. The non-PEGylated form has a very short half-life.
Full details →Side-by-Side Comparison
| Aspect | Exenatide | MGF (Mechano Growth Factor) |
|---|---|---|
| Mechanism | Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. | Activates muscle satellite cells (stem cells) and promotes their proliferation without differentiation, priming them for fusion with existing muscle fibers during repair and growth. |
| Typical Dosage | Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly. | Due to extremely short half-life (minutes), typical protocols use 100-200mcg injected directly into target muscles immediately post-workout. |
| Administration | Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe. | Intramuscular injection into trained muscles within minutes of workout completion. Must be used immediately after reconstitution due to instability. |
| Side Effects | Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon). | Injection site soreness, potential hypoglycemia, localized swelling. Short half-life limits systemic effects. |
| Best For |